BioCryst shares are blast­ed as a PhI­II HAE 'suc­cess' un­der­whelms an­a­lysts

It was de­signed to be the oral fix for hered­i­tary an­gioede­ma (HAE) — a rare, po­ten­tial­ly life-threat­en­ing ge­net­ic dis­or­der — but BioCryst Phar­ma­ceu­ti­cal’s ex­per­i­men­tal cap­sule has un­der­whelmed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER